Home » Salix Pharma Meets FDA on Content, Format of Pending NDA for Rifaximin
Salix Pharma Meets FDA on Content, Format of Pending NDA for Rifaximin
Salix Pharmaceuticals Ltd. reported that it held a pre-NDA meeting with the FDA to discuss the company’s proposed new drug application for rifaximin
in the treatment of patients with non-constipation irritable bowel syndrome.
RTTNews
RTTNews
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May